AGE-RELATED MACULAR DEGENERATION (ARMD)
Clinical trials for AGE-RELATED MACULAR DEGENERATION (ARMD) explained in plain language.
Never miss a new study
Get alerted when new AGE-RELATED MACULAR DEGENERATION (ARMD) trials appear
Sign up with your email to follow new studies for AGE-RELATED MACULAR DEGENERATION (ARMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New injection could halt leading cause of blindness in seniors
Disease control OngoingThis late-stage clinical trial is testing whether daily injections of an experimental drug called elamipretide can slow the progression of dry age-related macular degeneration (AMD), a leading cause of vision loss in older adults. The study involves 313 participants who will rece…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: PHASE3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Can your diet outsmart your genes for eye health?
Knowledge-focused OngoingThis study aims to understand how factors like diet, lifestyle, and medications interact with a person's genetics to influence their risk of developing age-related macular degeneration (AMD), a leading cause of vision loss. Researchers are following 1,800 adults in Portugal, coll…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: NA • Sponsor: Association for Innovation and Biomedical Research on Light and Image • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC